Drugs / RE104
RE104
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07146191 | Aug → Oct 2025 | — | Reunion Neuroscience Inc | Completed | No outcome recorded |
| Phase 1 | NCT06659263 | Nov 2024 → May 2025 | lactation disease | Reunion Neuroscience Inc | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07489651 | Apr 2026 → Feb 2027 expected | generalized anxiety disorder | Reunion Neuroscience Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT07002034 | Jul 2025 → Nov 2026 expected | adjustment disorder | Reunion Neuroscience Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT06342310 | Jun 2024 → May 2025 | postpartum depression | Reunion Neuroscience Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RE104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07489651 ↗ |
| Known as | 2-[14C]-RE104 | “2-[14C]-RE104 for Injection” NCT07146191 ↗ |
| Known as | RE104 for Injection | “A single subcutaneous injection of 30 mg RE104 for Injection” NCT07489651 ↗ |
| Route | Subcutaneous | “Single, subcutaneous dose of RE104 for Injection” NCT06342310 ↗ |